Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Anthracyclines plus fluoropyrimidines well tolerated and active in advanced breast cancer patients
December 22nd, 2005
Anthracyclines plus fluoropyrimidines were well tolerated and active in advanced breast cancer (ABC) patients. "The efficacy and safety of prolonged fluoropyrimidines, either intravenously or orally, prompted their integration with taxanes and anthracyclines in the treatment of ABC. We conducted three subsequent dose-finding studies on first-line chemotherapy in ABC with anthracyclines, either epirubicin (E) or doxorubicin (A), and docetaxel (T), both given on days 1 and 8 every 3 weeks, plus continuous infusion (CI) 5-fluorouracil (F) or capecitabine (X)," scientists in Switzerland reported. "Sixty-two patients (37% dominant visceral disease, 48%...
Source: Women's Health Weekly (2005-12-22)
|
